Marc Vervuurt

Altered brain expression and cerebrospinal fluid levels of TIMP4 in cerebral amyloid angiopathy

Lieke Jäkel, Anna M. de Kort, Arno Stellingwerf, Carla Hernández Utrilla et autres

Abstract Cerebral amyloid angiopathy (CAA) is a highly prevalent and progressive pathology, involving amyloid-β (Aβ) deposition in the cerebral blood vessel walls. CAA is associated with an increased risk for intracerebral hemorrhages (ICH). Insight into the molecular mechanisms associated with CAA pathology …

nl, be (code pays fourni par la source)

Proximity extension assay in cerebrospinal fluid identifies neurofilament light chain as biomarker of neurodegeneration in sporadic cerebral amyloid angiopathy

Marc Vervuurt, H. Bea Kuiperij, Anna M. de Kort, Iris Kersten et autres

BACKGROUND: Sporadic cerebral amyloid angiopathy (sCAA) is a disease characterised by the progressive deposition of the amyloid beta (Aβ) in the cerebral vasculature, capable of causing a variety of symptoms, from (mild) cognitive impairment, to micro- and major haemorrhagic lesions. Modern diagnosis …

nl (code pays fourni par la source)

Translational validation of shotgun proteomics findings in cerebrospinal fluid of sporadic cerebral amyloid angiopathy patients

Marc Vervuurt, Anna M. de Kort, Iris Kersten, Astrid van Rens et autres

Abstract Background Prior research conducted in model rats of CAA Type 1 (rTg-DI) identified a range of cerebrospinal fluid biomarker candidates associated with sCAA pathology. This list of potential biomarkers includes the lysosomal proteases cathepsins B and S (CTSB/CTSS) and hexosaminidase B …

nl, us (code pays fourni par la source)

Cerebrospinal fluid shotgun proteomics identifies distinct proteomic patterns in cerebral amyloid angiopathy rodent models and human patients

Marc Vervuurt, Joseph M. Schrader, Anna M. de Kort, Iris Kersten et autres

Cerebral amyloid angiopathy (CAA) is a form of small vessel disease characterised by the progressive deposition of amyloid β protein in the cerebral vasculature, inducing symptoms including cognitive impairment and cerebral haemorrhages. Due to their accessibility and homogeneous disease phenotypes, animal models …

nl, us (code pays fourni par la source)

Additional file 1 of Cerebrospinal fluid shotgun proteomics identifies distinct proteomic patterns in cerebral amyloid angiopathy rodent models and human patients

Marc Vervuurt, Joseph M. Schrader, Anna M. de Kort, Iris Kersten et autres

Additional file 1: Table S1. shows results of analysis in rTg-DI/WT rodents. Protein characteristics and identifiers are given (Protein.Ids/Gene.Ids/Gene.names/Protein.names). Filter shows which proteins adhered to the filtering step (1 = present in ≥75% of samples of either group; 0 = not present …

nl, us (code pays fourni par la source)

Shotgun proteomics for the discovery of protein biomarkers for cerebral amyloid angiopathy

Marc Vervuurt, H. Bea Kuiperij, Anna M. de Kort, Iris Kersten et autres

Abstract Background Oftentimes, the search for novel (protein) biomarkers starts in transgenic animal models, to minimize inter‐individual variation and confounding influences. In our search for novel biomarkers for cerebral amyloid angiopathy (CAA), we have executed shotgun proteomics analyses aimed at identifying novel …

nl, gb (code pays fourni par la source)

Decreased ratios of matrix metalloproteinases to tissue-type inhibitors in cerebrospinal fluid in sporadic and hereditary cerebral amyloid angiopathy

Marc Vervuurt, Anna M. de Kort, Lieke Jäkel, Iris Kersten et autres

BACKGROUND: To evaluate the potential of cerebrospinal fluid (CSF) levels of matrix metalloproteinases and tissue-type inhibitors (MMP; TIMP), and ratios of MMPs to TIMPs, to function as biomarkers for sporadic or hereditary cerebral amyloid angiopathy (CAA). METHODS: CSF concentrations of the matrix …

nl, us (code pays fourni par la source)

Elevated expression of urokinase plasminogen activator in rodent models and patients with cerebral amyloid angiopathy

Marc Vervuurt, Xiaoyue Zhu, Joseph M. Schrader, Anna M. de Kort et autres

AIMS: The aim of this work is to study the association of urokinase plasminogen activator (uPA) with development and progression of cerebral amyloid angiopathy (CAA). MATERIALS AND METHODS: We studied the expression of uPA mRNA by quantitative polymerase chain reaction (qPCR) and …

nl, us (code pays fourni par la source)

A disbalance of matrix metalloproteinases and their inhibitors in the cerebrospinal fluid from patients with cerebral amyloid angiopathy

H. Bea Kuiperij, Marc Vervuurt, Anna M. de Kort, Iris Kersten et autres

Abstract Background Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) are involved in extracellular matrix (ECM) modelling and regulation of basement membrane integrity. A chronic disbalance in the expression and activity of these proteinases and their inhibitors in favor of MMPs …

nl (code pays fourni par la source)

Urokinase plasminogen activator (uPA) as a novel biomarker for cerebral amyloid angiopathy

Marc Vervuurt, Xiaoyue Zhu, Joseph M. Schrader, Anna M. de Kort et autres

Abstract Background Diagnosis of the highly prevalent disease cerebral amyloid angiopathy (CAA) is mainly based on radiological identification of cerebral micro‐ or macrobleeds (according to the diagnostically acclaimed Boston Criteria) in the end‐stage of disease. Body fluid biomarkers (e.g. in cerebrospinal fluid) …

nl, us (code pays fourni par la source)

Elevated Expression of Urokinase Plasminogen Activator in Rodent Models and Patients With Cerebral Amyloid Angiopathy

Marc Vervuurt, Xiaoyue Aelita Zhu, Joseph M. Schrader, Anna M. de Kort et autres

nl, us (code pays fourni par la source)

Urokinase plasminogen activator (uPA) as a novel biomarker for cerebral amyloid angiopathy

Marc Vervuurt, Anna M. de Kort, Floris H.B.M. Schreuder, Catharina J.M. Klijn et autres

Abstract Background Current diagnostic criteria for cerebral amyloid angiopathy (CAA) are predominantly based on radiological identification of evidence of CAA (micro‐ or macrobleeds). These criteria present only end‐stage manifestations of the disease, however. The development of transgenic rat models for CAA, carrying …

nl (code pays fourni par la source)